Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific (BSX) to $122 from $119 and keeps a Strong Buy rating on the shares. Boston Scientific reported “stellar” Q4 results, exceeding high expectations and playing the “guidance game” well, the analyst tells investors in a research note. Boston Scientific has emerged as one of the fastest growing, and most dynamic, companies in Med Tech, the firm contends.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $120 from $110 at Truist
- Boston Scientific price target raised to $115 from $100 at Stifel
- Boston Scientific price target raised to $120 from $112 at Baird
- Boston Scientific price target raised to $117 from $101 at Canaccord
- Boston Scientific price target raised to $122 from $107 at Citi